SuperworthSummit Therapeutics shares outstanding SMMT
Diluted shares outstanding, averaged over each quarter, from 2019.
- Latest quarter, to Jun 30, 2026
- 778.2M
- On a year earlier
- +4.8%
- more shares
Summit Therapeutics had 778.2M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 4.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 766.4M | +4% |
| FY2024 | 737.5M | +5% |
| FY2023 | 700.6M | +144% |
| FY2022 | 286.8M | +206% |
| FY2021 | 93.6M | +23% |
| FY2020 | 76.4M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 778.2M | +5% | |
| Q1 FY26 | 775.5M | +5% | |
| Q4 FY25 | 766.4M | +4% | |
| Q3 FY25 | 743.4M | +2% | |
| Q2 FY25 | 742.6M | +5% | |
| Q1 FY25 | 738.1M | +5% | |
| Q4 FY24 | 737.5M | +5% | |
| Q3 FY24 | 726.7M | +4% | |
| Q2 FY24 | 707.9M | +1% | |
| Q1 FY24 | 701.8M | +86% | |
| Q4 FY23 | 700.6M | +144% | |
| Q3 FY23 | 697.7M | +234% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Summit Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.